HIGHLIGHTS
- who: Dirk Hose from the Germany Germany have published the Article: Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial, in the Journal: (JOURNAL)
- what: As the aim of the manuscript was prospective testing of the GEP-R, these examples include AURKA, FGFR3, and IGF1R, for which at that time potential clinical grade inhibitors were foreseen, (ii) potential targets for immunotherapy, i.e., cancer testis antigens like CTAG1, MAGE1, and HM1.24, and_(iii) genes frequently Although this is beyond . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.